In this study, we assessed the efficacy of NT-3 gene therapy using the AAVrh74 serotype in the <i>Mfn2</i><sup>+/-</sup> mouse model for CMT2A. Here, MFN2 is linked to Charcot-Marie-Tooth disease type 2A1.